Clinical Study of Guben Xiaoliu Capsule Combined with FOLFOX4 Regimen in Treating Advanced Colorect Cancer
Hu Fengshan, Zhang Qing, Wang Xiaomin, Yang Guowang, Zhao Wenshuo. Clinical Study of Guben Xiaoliu Capsule Combined with FOLFOX4 Regimen in Treating Advanced Colorect Cancer. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi. 2007, 14 (7): 13-14.
To observe effect of Guben Xiaoliu capsule combined with FOLFOX4 regimen in treating advanced colorectal cancer patients. 78 advanced colorectal cancer patients were randomly assigned to treatment group (38 patients) and control group (40 patients). Oxaliplatin 85 mg/m^2 IV infusion for 2 hours, dl. CF 200 mg/m^2 IV infusion for 2 hours followed by 5-FU 400 mg/m^2 iv infusion for 22 hours, d1-2.Every two weeks was a cycle. The control group was treated by FOLFOX4 regimen, while Guben Xiaoliu capsule was added in the treatment group. Patients were evaluated after 4 cycles. Clinical beneficial rate (CR＋PR＋SD) of treatment and contral group were 76.3% and 57.5% respectively (P<0.05). Guben Xiaoliu capsule decreased blood hypercoagulability, improved cellular immune function of patients, relieved myelosuppression of chemotherapeutic agents and improved quality of life of patients. FOLFOX4 regimen combined with Guben Xiaoliu capsule had better effect in the treatment of advance colorectal cancer patients.
Clinical Study on Treatment of Advanced Stage Non Small Cell Lung Cancer
Wang Xiaomin, Xin Hai, Yang Zhong, Zhao Wenshuo, Yang Guowang, Liu Ju, Tang Wujun, Zhang Qing, Han Dong, Yu Rencun. Clinical Study on Treatment of Advanced Stage Non Small Cell Lung Cancer. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 2004, 24 (11): 986-988.
To observe the therapeutic effect of Guben Xiaoliu Capsule (GXC) in treating advanced stage non small cell lung cancer (NSCLC). One hundred and ninety eight NSCLC in patients were divided into the integrative treated group (Group A, 54 patients treated with chemotherapy (CT) plus GXC), the TCM treated group (Group B, 96 patients treated with GXC alone) and the chemotherapeutic group (Group C, 48 patients treated with CT alone). Randomized controlled observation was applied to the Group A and C. The clinical effect, quality of life (QOL), adverse reaction and survival period in the three groups were observed. The immediate effective rate (CR+PR) in the Group A, B and C was 16 7%, 3 1% and 8 3%, respectively, in the Group A, it was better than that in the other two groups (P<0 05). The improvement of clinical symptoms and QOL in the Group A and B were superior to those in the Group C (P<0 05). The median survival rate in the three groups was 12, 15 and 9 months, respectively, the 1, 2 and 3 year survival rate in Group A being 57 4%, 11 1% and 3 7%, respectively, in Group B, 67 7%, 9 4% and 3 1%, and in Group C, 39 6%, 4 2% and 0, respectively, comparison between the three groups showed that the survival rates in the former two were higher than those in Group C (P<0 05). Moreover, the incidence rate and degree of CT toxicity were milder in Group A than those in Group C (P<0 05). GXC has definite effect in treating NSCLC, it could raise the QOL, prolong the survival period of patients, also reduce the toxicity and enhance the efficacy of CT.
Inhibitory Effect and Antiangiogenesis of Gubenxiaoliu Capsule on Lewis Lung Carcinoma of Mouse
Yang Guo-wang, Wang Xiao-min, Wang Zheng, Peng-Rui-yun, Gao Ya-bing, Wang Xiao-min. Inhibitory Effect and Antiangiogenesis of Gubenxiaoliu Capsule on Lewis Lung Carcinoma of Mouse. China Journal of Experimental Traditional Medical Formulae, 2004, 10 (5):50-52.
To explore the inhibitory effect of tumor growth and angiogenesis of Gubenxiaoliu capsule (GC) on Lewis lung carcinoma of mice. In vivo animal experiment was used to investigate the growth of mice tumors. Immunological (SP) and quantitative pathologic image analysis were used to investigate the microvessel density (MVD) and expression of vascular endothelial growth factor (VEGF) in tumor tissue. The inhibitory rates on mouse tumor of GC group, Chemotherapy group and GC Chemotherapy group are 40.58%, 52.69%, 61.09% respectively. The inhibitory rates are significantly higher than the control, while MVD and expression of VEGF of GC group and GC Chemotherapy group and MVD of Chemotherapy group decreased significantly. GC could inhibit the growth and angiogenesis of Lewis lung carcinoma of mice.